Skip to main content
NEUREN PHARMACEUTICALS LIMITED logo

NEUREN PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · NEU ISIN · NZNEUE0001S8 LEI · 984500E48D0FDEE7CE63 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,218 across all filing types
Latest filing 2026-05-13 Transaction in Own Shar…
Country NZ New Zealand
Listing ASX NEU

About NEUREN PHARMACEUTICALS LIMITED

https://www.neurenpharma.com/

Neuren Pharmaceuticals Limited is a biopharmaceutical company focused on developing innovative therapies for rare neurodevelopmental disorders. The company's lead product, trofinetide (marketed as DAYBUE), is the first treatment approved by the U.S. Food and Drug Administration for Rett syndrome in both adult and pediatric patients. Neuren is also advancing its second clinical-stage candidate, NNZ-2591, which is being evaluated in Phase 2 clinical trials for multiple serious conditions, including Phelan-McDermid, Angelman, Pitt-Hopkins, and Smith-Magenis syndromes. The company's research centers on synthetic analogs of naturally occurring molecules that regulate brain function, aiming to address significant unmet medical needs in patients with complex neurological impairments through rigorous clinical development and strategic commercial partnerships.

Recent filings

Filing Released Lang Actions
Update - Notification of buy-back - NEU 6 pages 18.2KB
Transaction in Own Shares Classification · 88% confidence The document is an ASX Appendix 3C notification detailing the daily on‐market buy‐back of the company’s own shares, including quantities, prices, dates, broker, and cumulative totals. This is clearly a report of the company’s share repurchase activity, matching the “Transaction in Own Shares (POS)” category.
2026-05-13 English
Update - Notification of buy-back - NEU 6 pages 18.2KB
Transaction in Own Shares Classification · 98% confidence The document is an ASX Appendix 3C Notification of buy-back providing daily updates on securities repurchased under an on-market buy-back. It reports the number of shares bought back, prices paid, and other buy-back details. This aligns with “Transaction in Own Shares” (share repurchase announcements).
2026-05-11 English
Notification of cessation of securities - NEU 4 pages 14.9KB
Transaction in Own Shares Classification · 95% confidence The document is an ASX Appendix 3H “Notification of cessation of securities” showing shares cancelled under an on-market buy-back. This is a direct report of the company buying back/cancelling its own shares and matches the Transaction in Own Shares category.
2026-05-11 English
Launch of Investor Hub to enhance shareholder engagement 2 pages 171.2KB
Regulatory Filings Classification · 71% confidence The document is an ASX announcement by Neuren Pharmaceuticals about the launch of an Investor Hub and new website. It does not contain financial results or detailed investor presentation slides, nor is it a formal regulatory certification or specific report. It is a general corporate announcement to shareholders and stakeholders. This fits the fallback category of general regulatory filings (RNS) for miscellaneous announcements that do not fit other specific categories.
2026-05-11 English
Update - Notification of buy-back - NEU 6 pages 18.2KB
Transaction in Own Shares Classification · 92% confidence The document is an ASX Appendix 3C daily notification of an on-market buy-back by Neuren Pharmaceuticals. It details the number of securities repurchased, price ranges, dates, and other buy-back specifics. This clearly falls under “Transaction in Own Shares” (share repurchase) rather than an announcement of another report or general regulatory filing.
2026-05-10 English
Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025 3 pages 253.8KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 7 May 2026 reporting Q1 2026 financial highlights, including net sales and royalty income for the drug DAYBUE®. It references Q1 2026 results and provides detailed financial figures and business updates. The document is about quarterly financial performance and includes substantive financial data and analysis for a period shorter than a full fiscal year. It is not a full annual report, nor is it a brief earnings release with only key highlights; it contains more detailed financial and operational information. It is not a report publication announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-05-06 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.